Live prices from 14 UK suppliers, from £17.95, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Cerebrolysin
Cerebrolysin
Cerebrolysin
Cerebrolysin 60mg
Cerebrolysin 60mg
Cerebrolysin 60mg
Cerebrolysin 60mg
Cerebrolysin 60mg
Compare 13 prices for Cerebrolysin. Cheapest: £17.95. Average: £38.79.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £41.00 | £0.68/mg | In Stock | Free over £100 |
Lab Tested
|
— | |||
| £17.95 | £0.30/mg | Out of Stock | Free over £75 |
Lab Tested
|
— | |||
| £34.99 | £0.58/mg | In Stock | Free |
Lab Tested
|
— | |||
| £19.95 | £0.33/mg | Out of Stock | Free |
—
|
— | |||
| £75.00 | £1.25/mg | In Stock | Free |
Lab Tested
|
— | |||
| £33.00 | £0.55/mg | In Stock | Free |
Lab Tested
|
— | |||
| £24.99 | £0.42/mg | In Stock | Free |
—
|
— | |||
| £25.00 £22.50 | £0.38/mg | In Stock | Free |
Lab Tested
|
pepsup10 10% off applied | |||
| £24.90 | £0.42/mg | In Stock | Free |
Lab Tested
|
— | |||
| £25.00 | £0.42/mg | In Stock | Free |
—
|
— | |||
| £25.00 | £0.42/mg | In Stock | Free over £200 |
Lab Tested
|
— | |||
| £30.00 | £0.50/mg | Out of Stock | £9.99 |
—
|
— | |||
| £130.00 | £2.17/mg | In Stock | Free |
Lab Tested
|
— | Unavailable |
More ways to compare Cerebrolysin
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Neuropeptide Preparation | Neurological Recovery
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Bioactive peptide mixture
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Some studies show enhanced recovery; results vary significantly between trials.
Early administration within 72 hours shows better outcomes than delayed treatment.
Primary administration route with well-established protocols for direct brain delivery via IV/IM.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Potential additive neurotropic effects; monitor for enhanced antidepressant effects.
May have additive neurological effects; requires careful monitoring.
Contraindicated per prescribing information; do not mix in same infusion.
Should not be mixed in same IV infusion per official guidelines.
Compatibility issues; do not mix in same IV infusion.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
Initial neuroprotective effects; possible mild side effects (dizziness, agitation)
Neurological improvements become apparent; cognitive function may begin to improve
Continued recovery; motor function improvements in stroke/TBI patients
Sustained benefits; cognitive enhancement plateaus in chronic conditions
The Cochrane database of systematic reviews · Ziganshina LE, Abakumova T, Hoyle CH
This Cochrane review assessed randomized trials in acute ischaemic stroke and reported no clear reduction in death or dependency, with concern about serious adverse events in the included evidence.
Stroke · Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators
This large randomized trial in acute ischemic stroke reported no significant overall difference on the primary 90-day global outcome between Cerebrolysin and placebo groups.
Stroke · Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A
This multicenter trial studied patients after ischemic stroke with motor impairment and reported higher 90-day motor-recovery scale scores in the Cerebrolysin group alongside standardized rehabilitation.
Journal of neuroscience research · Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG
This experimental stroke study reported increased markers of neurogenesis and better functional outcome measures in animals receiving Cerebrolysin after focal cerebral ischemia.
European journal of neurology · Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H
This randomized trial compared three Cerebrolysin dosing regimens with placebo in mild to moderate Alzheimer’s disease and reported dose-related differences on cognitive and global clinical scales.
Plain-English guides and study summaries from published literature.
Guides
7 min
The Neuroprotective Peptide Therapy Used for TBI, Stroke, and Cognitive Decline Research Traumatic brain injury, Alzheimer’s disease, stroke—these are some of the most life-altering conditions on earth. And the frustrating truth is that many traditional approaches are either limited, slow, or inconsistent.
Read article
Guides
5 min
Understanding Cerebrolysin: A Hidden Gem Cerebrolysin isn’t “new.” It’s been around far longer than most people realize—it just hasn’t been widely used in the places you’d expect, for the reasons you’d expect. Your most valuable asset is the three-pound universe between your ears. If that fails, everything fails. Cerebrolysin matters because it addresses the predictable ways the brain breaks down—at the mechanism level, not the symptom level.
Read articleBe the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.